Feed Top Reports Pricing

⌘K

00:15:13·25d

SECFiling

SEC Form EFFECT filed by Kazia Therapeutics Limited

KZIA· Kazia Therapeutics Limited

Health Care

Original source

Companies

KZIA
Kazia Therapeutics Limited
Health Care

Recent analyst ratings

Apr 15UpdateLaidlaw$25.00
Feb 6UpdateMaxim Group$3.00
Oct 14UpdateMaxim Group$18.00

Related

SEC8d
SEC Form 424B3 filed by Kazia Therapeutics Limited
SEC8d
SEC Form 424B3 filed by Kazia Therapeutics Limited
SEC8d
SEC Form 424B3 filed by Kazia Therapeutics Limited
SEC8d
SEC Form 424B3 filed by Kazia Therapeutics Limited
SEC8d
SEC Form 6-K filed by Kazia Therapeutics Limited
ANALYST8d
Laidlaw initiated coverage on Kazia Therapeutics with a new price target
PR8d
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
SEC10d
SEC Form 424B3 filed by Kazia Therapeutics Limited

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022